SEC Form 4 · accession 0001179110-16-018856

Editas Medicine, Inc. · EDIT

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director · 10% Owner

Period of report

Feb 8, 2016

Accepted (ET)

Feb 9, 2016 · 6:00 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001650664

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1,F2	Feb 8, 2016	C	2,549,435	—	A	2,549,435	I	See Footnote
Common Stock^F1,F2	Feb 8, 2016	C	2,021,269	—	A	4,570,704	I	See Footnote
Common Stock^F1,F2	Feb 8, 2016	C	85,469	—	A	4,656,173	I	See Footnote

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	D/I
Series A-1 Preferred Stock^F2,F1	—	Feb 8, 2016	C	6,628,542	D	—	—	Common Stock	2,549,435	I
Series A-2 Preferred Stock^F2,F1	—	Feb 8, 2016	C	5,255,300	D	—	—	Common Stock	2,021,269	I
Series B Preferred Stock^F2,F1	—	Feb 8, 2016	C	222,222	D	—	—	Common Stock	85,469	I

F1The Series A-1, Series A-2 and Series B Preferred Stock converted into Common Stock on a 2.6-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-1, Series A-2 and B Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
F2These shares are owned directly by Polaris Venture Partners VI, L.P. and Polaris Venture Partners Founders' Fund VI, L.P. (together with Polaris Venture Partners VI, L.P., the "Polaris Funds"). Polaris Venture Management Co. VI, L.L.C. ("Polaris Management") is the general partner of the Polaris Funds. Kevin Bitterman has an assignee interest in Polaris Management. Kevin Bitterman disclaims beneficial ownership of all the shares held by the Polaris Funds except to the extent of his pecuniary interest therein.